4 trends tracked about this subject — the full history, oldest to newest below.
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
New analysis suggests that weight loss achieved through obesity drugs does not necessarily translate into improved mental health or better job prospects.
Insurance executives and employers are redefining access to GLP-1 weight-loss medications amid shifting coverage trends and affordability challenges.
Medicare has introduced a temporary pilot program designed to expand patient access to GLP-1 weight-loss medications.